Division of Rheumatology, Department of Medicine, Research Institute of the McGill University Health Centre, Montreal, Quebec H3G 1A4, Canada.
Section of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois 60680; Section of Nephrology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612.
J Biol Chem. 2011 Dec 9;286(49):42494-42503. doi: 10.1074/jbc.M111.230383. Epub 2011 Sep 29.
β(2)-Glycoprotein I (β(2)GPI) is an abundant plasma protein that binds to the surface of cells and particles expressing negatively charged lipids, but its physiological role remains unknown. Antibodies to β(2)GPI are found in patients with anti-phospholipid syndrome, a systemic autoimmune disease associated with vascular thrombosis and pregnancy morbidity. Although it has been suggested that anti-β(2)GPI antibodies activate endothelial cells and monocytes by signaling through TLR4, it is unclear how anti-β(2)GPI antibodies and/or β(2)GPI interact with TLR4. A number of mammalian proteins (termed "endogenous Toll-like receptor (TLR) ligands") have been reported to bind to TLR4, but, in most cases, subsequent studies have shown that LPS interaction with these proteins is responsible for TLR activation. We hypothesized that, like other endogenous TLR ligands, β(2)GPI interacts specifically with LPS and that this interaction is responsible for apparent TLR4 activation by β(2)GPI. Here, we show that both LPS and TLR4 are required for β(2)GPI to bind to and activate macrophages. Untreated β(2)GPI stimulated TNF-α production in TLR4-sufficient (but not TLR4-deficient) macrophages. In contrast, neither polymyxin B-treated nor delipidated β(2)GPI stimulated TNF-α production. Furthermore, β(2)GPI bound to LPS in a specific and dose-dependent manner. Finally, untreated β(2)GPI bound to the surface of TLR4-sufficient (but not TLR4-deficient) macrophages. Polymyxin B treatment of β(2)GPI abolished macrophage binding. Our findings suggest a potential new biological activity for β(2)GPI as a protein that interacts specifically with LPS and point to the need to evaluate newly discovered endogenous TLR ligands for potential interactions with LPS.
β(2)-糖蛋白 I (β(2)GPI) 是一种丰富的血浆蛋白,可与表达带负电荷脂质的细胞和颗粒表面结合,但它的生理作用仍不清楚。抗磷脂综合征患者存在针对β(2)GPI 的抗体,这是一种与血管血栓形成和妊娠发病率相关的系统性自身免疫性疾病。尽管已经提出抗β(2)GPI 抗体通过 TLR4 信号通路激活内皮细胞和单核细胞,但尚不清楚抗β(2)GPI 抗体和/或β(2)GPI 如何与 TLR4 相互作用。已经报道了许多哺乳动物蛋白(称为“内源性 Toll 样受体 (TLR) 配体”)与 TLR4 结合,但在大多数情况下,随后的研究表明 LPS 与这些蛋白的相互作用是 TLR 激活的原因。我们假设,与其他内源性 TLR 配体一样,β(2)GPI 与 LPS 特异性结合,这种相互作用是β(2)GPI 激活 TLR4 的原因。在这里,我们表明 LPS 和 TLR4 都是β(2)GPI 与巨噬细胞结合并激活巨噬细胞所必需的。未经处理的β(2)GPI 可刺激 TLR4 充足(但不是 TLR4 缺陷)的巨噬细胞产生 TNF-α。相比之下,多粘菌素 B 处理或去脂化的β(2)GPI 均未刺激 TNF-α 产生。此外,β(2)GPI 以特异性和剂量依赖性方式与 LPS 结合。最后,未经处理的β(2)GPI 与 TLR4 充足(但不是 TLR4 缺陷)的巨噬细胞表面结合。多粘菌素 B 处理的β(2)GPI 消除了巨噬细胞的结合。我们的发现表明β(2)GPI 作为一种与 LPS 特异性结合的蛋白质具有潜在的新生物学活性,并指出需要评估新发现的内源性 TLR 配体与 LPS 之间的潜在相互作用。